MISC

2008年9月

AST-120 (Kremezin (R)) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects

DIABETES RESEARCH AND CLINICAL PRACTICE
  • Kazunori Konishi
  • ,
  • Shigeru Nakano
  • ,
  • Shin-ichi Tsuda
  • ,
  • Atsushi Nakagawa
  • ,
  • Toshikazu Kigoshi
  • ,
  • Daisuke Koya

81
3
開始ページ
310
終了ページ
315
記述言語
英語
掲載種別
DOI
10.1016/j.diabres.2008.04.024
出版者・発行元
ELSEVIER IRELAND LTD

There is little clinical evidence when AST-120 should be prescribed for subjects with early stage overt diabetic nephropathy. We therefore designed a prospective, randomized, controlled study for subjects with type 2 diabetes (serum creatinine <1.5 mg/dl and urinary protein >0.5 g/day) in November, 2001. The primary end point was defined as exceeding 2 mg/dl of serum creatinine, and the secondary end point was defined as introducing a hemodialysis. Twenty-two subjects were selected, and after excluding 6 drop-out subjects, 16 subjects (10 in the control group; 6 in the KRM group) finally entered the study. Mean follow-up periods were 37 and 34 months in the control and KRM groups, respectively. There was no difference in clinical characteristics including renal dysfunction at baseline between the two groups. There was a significant reduction in urinary indoxyl sulfate at month 12 in the KRM group than in the control group. A significant difference was observed in changes in mean levels of serum creatinine versus time between the two groups. The primary end points were counted in 7 (70%) of the control subjects, while only 1 (17%) of the KRM group, and the Kaplan-Meier analysis was statistically significant. Although 4 (40%) of the control group and 1 (17%) of the KRM group were initiated hemodialysis as the secondary end point, the difference did not reach a statistical significance. Thus, we concluded that administration of AST-120 initiated in early stage overt diabetic nephropathy stunts the progression of renal dysfunction. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Web of Science ® 被引用回数 : 52

リンク情報
DOI
https://doi.org/10.1016/j.diabres.2008.04.024
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000259388300007&DestApp=WOS_CPL

エクスポート
BibTeX RIS